1. Home
  2. ANAB

as 05-17-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Founded: 2005 Country:
United States
United States
Employees: 117 City: SAN DIEGO
Market Cap: 695.8M IPO Year: 2017
Target Price: $46.22 AVG Volume (30 days): 368.1K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -6.14 EPS Growth: N/A
52 Week Low/High: $13.36 - $27.50 Next Earning Date: 05-09-2024
Revenue: $22,962,000 Revenue Growth: 114.78%
Revenue Growth (this year): -8.78% Revenue Growth (next year): 28.03%

Share on Social Networks:

Stock Insider Trading Activity of AnaptysBio Inc. (ANAB)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
MULROY DENNIS ANAB CHIEF FINANCIAL OFFICER Jan 30 '24 Sell $23.63 3,065 $72,425.34 964 SEC Form 4
Lizzul Paul F. ANAB Chief Medical Officer Jan 6 '24 Sell $21.81 2,554 $55,702.74 10,118 SEC Form 4
LOUMEAU ERIC J ANAB Chief Legal Officer Jan 6 '24 Sell $21.81 2,305 $50,272.05 3,240 SEC Form 4
LOUMEAU ERIC J ANAB Chief Legal Officer Nov 22 '23 Sell $14.19 882 $12,515.58 0 SEC Form 4